Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Open Access
- 25 January 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cardiovascular Diabetology
- Vol. 20 (1), 1-17
- https://doi.org/10.1186/s12933-020-01209-y
Abstract
Background: Although the benefits of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular events have been reported in patients with type 2 diabetes mellitus (T2DM) with or without heart failure (HF), the impact of SGLT2i on cardiac remodelling remains to be established. Methods: We searched the PubMed, Embase, Cochrane Library and Web of Science databases up to November 16th, 2020, for randomized controlled trials reporting the effects of SGLT2i on parameters of cardiac structure, cardiac function, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level or the Kansas City Cardiomyopathy Questionnaire (KCCQ) score in T2DM patients with or without chronic HF. The effect size was expressed as the mean difference (MD) or standardized mean difference (SMD) and its 95% confidence interval (CI). Subgroup analyses were performed based on the stage A–B or stage C HF population and HF types. Results: Compared to placebo or other antidiabetic drugs, SGLT2i showed no significant effects on left ventricular mass index, left ventricular end diastolic volume index, left ventricular end systolic volume index, or left atrial volume index. SGLT2i improved left ventricular ejection fraction only in the subgroup of HF patients with reduced ejection fraction (MD 3.16%, 95% CI 0.11 to 6.22, p = 0.04; I2 = 0%), and did not affect the global longitudinal strain in the overall analysis including stage A–B HF patients. SGLT2i showed benefits in the E/e’ ratio (MD − 0.45, 95% CI − 0.88 to − 0.03, p = 0.04; I2 = 0%), plasma NT-proBNP level (SMD − 0.09, 95% CI − 0.16 to − 0.03, p = 0.004; I2 = 0%), and the KCCQ score (SMD 3.12, 95% CI 0.76 to 5.47, p = 0.01; I2 = 0%) in the overall population. Conclusion: The use of SGLT2i was associated with significant improvements in cardiac diastolic function, plasma NT-proBNP level, and the KCCQ score in T2DM patients with or without chronic HF, but did not significantly affect cardiac structural parameters indexed by body surface area. The LVEF level was improved only in HF patients with reduced ejection fraction.Keywords
Funding Information
- the Key Projects in the National Science and Technology Pillar Program of the 13th Five-Year Plan Period (2017YFC1308300)
This publication has 80 references indexed in Scilit:
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart FailureJACC: Heart Failure, 2015
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile rangeBMC Medical Research Methodology, 2014
- Changes of Natriuretic Peptides Predict Hospital Admissions in Patients With Chronic Heart FailureJACC: Heart Failure, 2014
- Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection FractionJournal of the American College of Cardiology, 2013
- Cognitive-behavioural interventions for children who have been sexually abusedEmergencias, 2012
- Meta‐analysis of skewed data: Combining results reported on log‐transformed or raw scalesStatistics in Medicine, 2008
- Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeEuropean Heart Journal, 2008
- Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: The Cardiovascular Health StudyJournal of the American College of Cardiology, 2004
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyThe New England Journal of Medicine, 1990